EUVIMEDEUVIMED entdecken
KommentarOpen Access · CC BY-NC-ND 4.0

Evaluation of contemporary olanzapine- and netupitant/palonosetron-containing antiemetic regimens for chemotherapy-induced nausea and vomiting

C Ch Yip, L Li, T K H Lau, V T C Chan, C C H Kwok, J J S Suen, F K F Mo, W Yeo

Hong Kong Medical Journal · 2023

DOI: 10.12809/hkmj209182 ↗

Kurz gefasst

Kommentar in der Zeitschrift Hong Kong Medical Journal, 2023. Verfasst von C Ch Yip und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong. Hauptthemen laut MEDLINE: Antiemetics, Breast Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: This post-hoc analysis retrospectively assessed data from two recent studies of antiemetic regimens for chemotherapy-induced nausea and vomiting (CINV). The primary objective was to compare olanzapine-based versus netupitant/palonosetron (NEPA)-based regimens in terms of controlling CINV during cycle 1 of doxorubicin/cyclophosphamide (AC) chemotherapy; secondary objectives were to assess quality of life (QOL) and emesis outcomes over four cycles of AC. METHODS: This study included 120 Chinese patients with early-stage breast cancer who were receiving AC; 60 patients received the olanzapine-based antiemetic regimen, whereas 60 patients received the NEPA-based antiemetic regimen. The olanzapine-based regimen comprised aprepitant, ondansetron, dexamethasone, and olanzapine; the NEPA-based regimen comprised NEPA and dexamethasone. Patient outcomes were compared in terms of emesis control and QOL. RESULTS: During cycle 1 of AC, the olanzapine group exhibited a higher rate of 'no use of rescue therapy' in the acute phase (olanzapine vs NEPA: 96.7% vs 85.0%, P=0.0225). No parameters differed between groups in the delayed phase. The olanzapine group had significantly higher rates of 'no use of rescue therapy' (91.7% vs 76.7%, P=0.0244) and 'no significant nausea' (91.7% vs 78.3%, P=0.0408) in the overall phase. There were no differences in QOL between groups. Multiple cycle assessment revealed that the NEPA group had higher rates of total control in the acute phase (cycles 2 and 4) and the overall phase (cycles 3 and 4). CONCLUSION: These results do not conclusively support the superiority of either regimen for patients with breast cancer who are receiving AC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntiemeticsBreast NeoplasmsAntineoplastic AgentsHumansFemalePalonosetronOlanzapineQuality of LifeRetrospective StudiesDexamethasoneVomitingNauseaPiperazinesPyridinesBenzeneacetamides

Stichwörter der Autor:innen

NetupitantOlanzapinePalonosetron

Substanzen

AntiemeticsPalonosetronOlanzapineDexamethasoneAntineoplastic AgentsnetupitantPiperazinesPyridinesBenzeneacetamides

Autor:innen und Institutionen

  • Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong.
  • Department of Clinical Oncology, Princess Margaret Hospital, Hong Kong.

Zitieren

APA

Yip, C. C., Li, L., Lau, T. K. H., Chan, V. T. C., Kwok, C. C. H., Suen, J. J. S., Mo, F. K. F., & Yeo, W. (2023). Evaluation of contemporary olanzapine- and netupitant/palonosetron-containing antiemetic regimens for chemotherapy-induced nausea and vomiting. Hong Kong Medical Journal. https://doi.org/10.12809/hkmj209182

Vancouver

Yip CC, Li L, Lau TKH, Chan VTC, Kwok CCH, Suen JJS, et al. Evaluation of contemporary olanzapine- and netupitant/palonosetron-containing antiemetic regimens for chemotherapy-induced nausea and vomiting. Hong Kong Medical Journal. 2023. doi:10.12809/hkmj209182

BibTeX
@article{Yip2023,
  author = {Yip, C Ch and Li, L and Lau, T K H and Chan, V T C and Kwok, C C H and Suen, J J S and Mo, F K F and Yeo, W},
  title = {Evaluation of contemporary olanzapine- and netupitant/palonosetron-containing antiemetic regimens for chemotherapy-induced nausea and vomiting},
  journal = {Hong Kong Medical Journal},
  year = {2023},
  doi = {10.12809/hkmj209182}
}
Kostenlos starten →